Company Evelo Biosciences, Inc.

Equities

EVLO

US2997342025

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - OTC Markets Other stock markets 03:47:28 2024-04-19 pm EDT			5-day change	1st Jan Change
0.0495 ^USD	-1.00%		-1.98%	-19.51%

Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ
Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Number of employees: 66

Managers	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	63	Nov. 20
Andrea Itano CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Duncan McHale CTO	Chief Tech/Sci/R&D Officer	57	18-01-31
Chun Zhang CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Mark W. Bodmer CTO	Chief Tech/Sci/R&D Officer	69	16-01-18
Mark D. Plinio PRN	Corporate Officer/Principal	57	21-06-13
Leslie Wardwell-Scott PRN	Corporate Officer/Principal	-	-
Julie Carretero HRO	Human Resources Officer	-	20-09-13
Stuart Abel LAW	General Counsel	-	18-12-31

Members of the board	Title	Age	Since
Craig Jalbert CEO	Chief Executive Officer	63	Nov. 20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,930,960	18,905,228 ( 99.86 %)	0	99.86 %

Name	Equities	%	Valuation
Horizon Technology Finance Management LLC 11.40 %	2,164,502	11.40 %	97 403 $
DNCA Finance SA 1.416 %	268,822	1.416 %	12 097 $
Acadian Asset Management LLC 0.2517 %	47,775	0.2517 %	2 150 $
Mark W. Bodmer 0.1356 %	25,732	0.1356 %	1 158 $
Ann Thorell 0.1200 %	22,778	0.1200 %	1 025 $
Simba Gill 0.1037 %	19,688	0.1037 %	886 $
Duncan McHale 0.0895 %	16,984	0.0895 %	764 $
Saint Olive Gestion SNC 0.0738 %	14,000	0.0738 %	630 $
XTX Topco Ltd. 0.0537 %	10,189	0.0537 %	459 $
Jose-Carlos Gutiérrez-Ramos 0.002634 %	500	0.002634 %	23 $

Evelo Biosciences, Inc.

One Kendal Square, 600/700 Suite 7-201

02139, Cambridge

http://www.evelobio.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
EVELO BIOSCIENCES, INC.	-19.51%	949K
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs